Morepen Laboratories Ltd
Morepen Laboratories Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Morepen Laboratories Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Standalone Gross Revenue (Rs. Q1'FY26 Financials (Standalone): - EBITDA: Rs.
From Morepen Laboratories Ltd's Q1 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Standalone Gross Revenue (Rs. Crores):
- Q1'FY25: 385
- Q1'FY26 (Standalone): 395 (+2.6% YoY)
- Q1'FY26 (Consolidated): 430
- Pharma Business Total Revenue (Rs. Crores):
- Q1'FY25: 250
- Q1'FY26: 235 (-6% YoY)
- Pharma API Revenue (Rs. Crores):
- Q1'FY25: 224
- Q1'FY26: 205 (-8.5% YoY)
- Medical Devices Total Revenue (Rs. Crores):
- Q1'FY25: 443
- Q1'FY26: 496 (+12% YoY)
- Glucometer Sales:
- >1.06 million units sold in Q1'FY26 (72% YoY increase)
- BP Meter Sales:
- 3.37 crores revenue in Q1'FY26 vs. 3.17 crores in Q1'FY25
- Outlook:
2 more points management made on revenue & sales performance
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Plans to add 1000 Medical Representatives over 3 years to strengthen Pharma Business/RX segment (Page 26).
- Pharma Business/Finished Dosages segment: Addition of 2 new product lines in Q1 FY26 indicating capacity/product portfolio expansion (Page 25).
- No specific capital expenditure amounts, dedicated new plant constructions, or timelines for projects explicitly stated in the presentation.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key concall takeaways from Influx Healthtech Ltd's Q1 FY26…
Frequently Asked Questions
What were Morepen Laboratories Ltd Q1 FY26 results?
Standalone Gross Revenue (Rs. Q1'FY26 Financials (Standalone): - EBITDA: Rs.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Plans to add 1000 Medical Representatives over 3 years to strengthen Pharma Business/RX segment (Page 26).
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.